Recently, a phase III clinical trial, IMpower-110, has proved that PD-L1 inhibitor atezolizumab monotherapy provided longer overall survival (OS) and progression-free survival (PFS) in comparison with standard chemotherapy in the first-line treatment of metastatic NSCLC (4), and a better benefit was observed in a higher PD-L1 expression level subgroup (≥50%). Here, CD274 is linked to non-small cell lung carcinoma.